Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of LY3493269 in Healthy Participants
NCT04178733Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2020
- Primary completion
- May 2020
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LY3493269 in type 2 diabetes mellitus (T2DM) and obesity (5 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants With One or More Serious Adverse Event(s) Considered by the Investigator to be Related to Study Drug Administration. Started Jan 2020; status: completed.
02
Drugs
LY3493269
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT04178733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04178733.